You just read:

Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial

News provided by

Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Oct 10, 2018, 06:30 ET